SCHEMBL2947144

SCHEMBL2947144

CCCOc1ccc(N)nn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.47
BCAT2 O15382 1/20 0.44
MAPT P10636 4/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HTT P42858 2/20 0.42
USP2 O75604 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
ATM Q13315 1/20 0.42
TLR8 Q9NR97 1/20 0.40
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4269009 0.87 NPC1 (0.45) MCHR1MAPTKDM4EALDH1A1MEN1
SCHEMBL2349832 0.83 BCAT2 (0.47) MCHR1BCAT2MAPTKDM4EALDH1A1
SCHEMBL31206831 0.83 BCAT2 (0.47) MCHR1BCAT2MAPTKDM4EALDH1A1
SCHEMBL30508584 0.82 BCAT2 (0.43) BCAT2ALDH1A1GAAMAPK1LMNA
SCHEMBL28670188 0.80 BCAT2 (0.44) MCHR1BCAT2MAPT
SCHEMBL18291611 0.79 HTR7 (0.46) BCAT2
SCHEMBL25318049 0.78 NCF1 (0.41) BCAT2
SCHEMBL4026841 0.78 BCAT2 (0.40) MCHR1BCAT2GAAMAPK1LMNA
SCHEMBL4273729 0.76 RAB9A (0.56) MCHR1MAPTKDM4EALDH1A1TLR8
SCHEMBL6939611 0.76 CHRNB2 (0.42) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7759349-B2 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) 2010-07-20 US disclosed
CN-100582108-C Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING PLOUGH ANIMAL HEALTH 2010-01-20 CN disclosed
EP-1699799-B1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES SCHERING PLOUGH LTD (CH) 2007-05-16 EP disclosed
CN-1922181-A Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING PLOUGH ANIMAL HEALTH (CH) 2007-02-28 CN disclosed
EP-1699799-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES Schering-Plough Ltd. (CH) 2006-09-13 EP disclosed
US-20050182059-A1 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives SCHERING-PLOUGH ANIMAL HEALTH CORPORATION 2005-08-18 US disclosed
WO-2005066177-A1 CONTROL OF PARASITES IN ANIMALS BY THE USE OF IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES SCHERING-PLOUGH LTD. (CH) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182059-A1 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives PLPBP, PIR, PPIP5K2 MCHR1 909/4885BCAT2 2343/4885MAPT 4648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.